Macerich Company (The) Common Stock vs Sana Biotechnology Inc — how do they compare? Macerich Company (The) Common Stock trades at $22.18 (market cap $6.29B), while Sana Biotechnology Inc trades at $2.33 (market cap $697.51M). The key difference: Macerich Company (The) Common Stock is far larger — about 9× Sana Biotechnology Inc's market cap, and Macerich Company (The) Common Stock pays a 3.07% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macerich Company (The) Common Stock for 0 Days and Sana Biotechnology Inc for 24 Days on average.
| MAC | SANA | |
|---|---|---|
Market Cap | $6.29B | $697.51M |
Volume | 3,158,142 | 2,763,583 |
Sector | Real Estate | Health |
52-Week High | $26.51 | $5.92 |
52-Week Low | $16.20 | $2.33 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $10.97B | $610.76M |
Dividend Yield | 3.07% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.41, down 8.02% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company shows no revenue with substantial losses (-$244.17M net income in 2025) and negative cash flow, though analyst consensus remains strongly positive with 82% buy ratings. Recent investor conference presentations indicate active business development efforts.
The stock presents high-risk speculative potential with strong Wall Street support but faces fundamental challenges including no revenue generation and significant cash burn. Investment opportunity hinges on successful clinical developments, while risks include continued operational losses and potential dilution from financing activities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.
Read more on MAC →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →